Clinical Trial Update: Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure [Phase 3]

View source ↗

Summary

A Phase 3 population PK study evaluating multiple 10 mg/kg doses of daptomycin (Cubicin) in critically ill patients with bacteremia, endocarditis, or skin and s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Endocarditis
• Renal Failure
• Skin and Soft Tissue Infection

Drugs mentioned

• Cubicin (daptomycin)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Renal Failure, Critical Care | Phase 3 | Status: COMPLETED